Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report released on Friday, AnalystRatings.com reports. They currently have a $18.00 price objective on the stock. Needham & Company LLC’s target price would suggest a potential upside of 328.57% from the stock’s previous close.
Separately, Zacks Investment Research raised Trevi Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, October 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $16.75.
TRVI stock traded up $0.30 during trading hours on Friday, hitting $4.20. 15,100 shares of the stock were exchanged, compared to its average volume of 17,847. The firm has a 50-day moving average price of $3.86. Trevi Therapeutics has a 12 month low of $2.65 and a 12 month high of $10.62.
Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Trevi Therapeutics during the second quarter valued at about $26,000. Morgan Stanley bought a new position in shares of Trevi Therapeutics during the second quarter worth about $42,000. Northern Trust Corp bought a new position in shares of Trevi Therapeutics during the second quarter worth about $124,000. Vanguard Group Inc. bought a new position in shares of Trevi Therapeutics during the second quarter worth about $886,000. Finally, Omega Fund Management LLC bought a new position in shares of Trevi Therapeutics during the second quarter worth about $9,476,000. 79.55% of the stock is currently owned by hedge funds and other institutional investors.
Trevi Therapeutics Company Profile
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Further Reading: The mechanics of the bid-ask spread in trading
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.